Study on the efficacy, safety, and biomarkers of nusinersen in type II and III spinal muscular atrophy in children.

Front Pediatr · 2023 · PMC10725990 · PMID 38111627

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

After each treatment with nusinersen, platelets showed a decreasing trend ( P 1 = 0.008, P 2 < 0.001, P 3 < 0.001, P 4 = 0.021; Figure 4 ), and platelets rebounded again before the next treatment with nusinersen. 3.6.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.